-+ 0.00%
-+ 0.00%
-+ 0.00%

Traws Pharma Completed Clinical Analysis Of Its 90-patient, Open-label Phase 2 Study Of Ratutrelvir Versus Paxlovid For Mild-to-moderate Covid-19

Benzinga·02/19/2026 12:36:18
Listen to the news
  • Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID®-ineligible patients, representing a significant population with no effective treatment options
  • Pre-clinical analysis of tivoxavir marboxil tablets demonstrated significantly increased exposure compared to a prototype formulation with predicted 28-day protection in humans from influenza infections against a wide range of seasonal and pandemic variants
  • PK study of compressed tivoxavir marboxil tablets submitted under open IND in Australia and preparations are underway for a Human Influenza Prophylaxis Challenge Study in the UK